Japanese recommendation takes Sanwa's anagliptin closer to first market
This article was originally published in Scrip
Executive Summary
Sanwa Kagaku Kenkyusho/Kowa's anagliptin (SK-0403) has moved a step closer to becoming the sixth DPP-4 inhibitor to be launched in Japan following a positive approval recommendation for the treatment of type 2 diabetes.
You may also be interested in...
Daiichi’s EZH Contender Moves Ahead In Leukemia/Lymphoma
Japanese company starts pivotal trial with novel molecule as it looks to build oncology presence.
Gene And Cell Therapies In Asia: Pricing, Manufacturing Stand-Out Issues in Supportive Japan Ecosystem
The Japanese environment for cell and gene therapies and regenerative medicine in general continues to be highly supportive. But will pricing pressures under the NHI scheme move to the fore as more expensive products come to market?
Asia Deal Watch: Fujifilm Affiliate Out-Licenses Antifungal Candidate To Canada’s Appili
Novel antifungal T-2307, discovered by FUJIFILM Toyama, works by selectively disrupting mitochondrial function. Excelra and Maruho team up to repurpose existing drugs.
Need a specific report? 1000+ reports available
Buy Reports